



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Antibiotic and Antimalarial Quinones from Fungus-Growing Ant-Associated *Pseudonocardia* sp.

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Carr, Gavin, Emily R. Derbyshire, Eric Caldera, Cameron R. Currie, and Jon Clardy. 2012. Antibiotic and antimalarial quinones from fungus-growing ant-associated <i>Pseudonocardia</i> sp. <i>Journal of Natural Products</i> 75(10): 1806-1809.
Published Version	doi:10.1021/np300380t
Accessed	February 19, 2015 11:51:03 AM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:10511078
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

Antibiotic and Antimalarial Quinones from Fungus-Growing Ant-Associated *Pseudonocardia* sp.


Gavin Carr,[†] Emily R. Derbyshire,[†] Eric Caldera,[‡] Cameron R. Currie,[‡] and Jon Clardy^{*,†}

[†]Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States


[‡]Department of Bacteriology, University of Wisconsin–Madison, Madison, Wisconsin 53706, United States

S Supporting Information

ABSTRACT: Three new members of the angucycline class of antibiotics, pseudonocardones A–C (1–3), along with the known antibiotics 6-deoxy-8-*O*-methylrabelomycin (4) and X-14881 E (5) have been isolated from the culture of a *Pseudonocardia* strain associated with the fungus-growing ant *Apterostigma dentigerum*. Compounds 4 and 5 showed antibiotic activity against *Bacillus subtilis* 3610 and liver-stage *Plasmodium berghei*, while 1–3 were inactive or only weakly active in a variety of biological assays. Compound 5 also showed moderate cytotoxicity against HepG2 cells.



Bacteria of the genus *Pseudonocardia* associate with fungus-growing ants¹ and produce antibiotics that presumptively play a role in suppressing fungal pathogens in ants' gardens.^{2,3} While *Pseudonocardia* belongs to the Actinomycetales, which are well known for their remarkable ability to produce bioactive secondary metabolites, relatively few natural products have been described from *Pseudonocardia* spp. Antibiotics discovered from *Pseudonocardia* spp. include dentigerumycin,³ pseudonocardians A and B,⁴ phenazostatin D,⁵ and NPP.⁶ Of these, only dentigerumycin was discovered from a *Pseudonocardia* strain associated with fungus-growing ants, and these symbionts likely have many more undiscovered natural products. As part of our ongoing effort to explore natural products from bacterial symbionts,^{3,7–9} we have investigated the natural products from *Pseudonocardia* sp. EC080529-01, isolated from the cuticle of the fungus-growing ant *Apterostigma dentigerum*.¹⁰ This strain produces three new members of the angucycline family of antibiotics,¹¹ pseudonocardones A (1), B (2), and C (3), along with the known antibiotics 6-deoxy-8-*O*-methylrabelomycin (4)¹² and X-14881 E (5).¹³



Pseudonocardia sp. EC080529-01 was grown on solid ISP-2 medium, and the agar was extracted with EtOAc followed by MeOH. HPLC-MS analysis of the EtOAc extract revealed two peaks with interesting UV spectra (λ_{\max} at 381 and 410 nm, respectively). HPLC-MS analysis of the MeOH extract revealed three additional polar peaks with λ_{\max} at 348 nm, 388, and 409 nm, respectively. Production cultures of *Pseudonocardia* sp. EC080529-01 were grown on solid ISP-2 medium and extracted with EtOAc followed by MeOH. The EtOAc extract was purified (see Experimental Section) to give 6-deoxy-8-*O*-methylrabelomycin (4, 8.3 mg) and X-14881 E (5, 3.5 mg). The MeOH extract was purified (see Experimental Section) to give pseudonocardones A (1, 2.0 mg), B (2, 0.9 mg), and C (3, 1.8 mg). The known compounds 4 and 5 were identified by 1D and 2D NMR spectroscopy, and their structures were confirmed by comparison of their spectroscopic data with the literature values.^{12,13}

Pseudonocardone A (1) gave a peak in the HRESI(+) MS consistent with a molecular formula of $C_{26}H_{24}O_{10}$. The NMR data (Figures 1 and 2 and Table 1) obtained for 1 indicated that it was related to the angucycline family of antibiotics and that it was similar in structure to 5. The peak in the UV spectrum of 5 at $\lambda_{\max} = 410$ nm had shifted to $\lambda_{\max} = 348$ nm. While compound 5 showed two carbon resonances typical of a quinone (δ_C 191.3 and 182.0), compound 1 showed only one carbon resonance in this range (δ_C 186.0). Instead, compound 1 showed a signal for an oxygenated methine resonance (δ_C 66.5; δ_H 6.93). This methine resonance showed HMBC correlations to C-6a (δ_C 132.5), C-7a (δ_C 120.8), C-11 (δ_C 123.8), C-11a (δ_C 147.7), C-12a (δ_C 139.6), and C-12b

Received: May 30, 2012

Published: October 1, 2012




Figure 1. Key COSY and HMBC correlations in the aglycone moiety of pseudonocardone A (1).




Figure 2. Key COSY and HMBC correlations in the sugar moiety of pseudonocardone A (1).

(121.6), indicating that C-12 is reduced in **1** to give a hydroquinone tautomer rather than a quinone as found in **5**.

Additional signals were present in the NMR spectra of **1** that could not be attributed to the angucycline core. Subtracting the atoms accounted for by the hydroquinone substructure showed that the remaining fragment had to account for $C_6H_9O_6$. A series of oxygenated methine resonances in the HSQC spectrum (δ_C 73.1–77.1 and δ_H 3.63–4.16) and a resonance typical of an anomeric carbon (δ_C 103.8 and δ_H 5.23) suggested that **1** was glycosylated. An HMBC correlation from the anomeric proton at δ_H 5.23 to δ_C 156.9 (C-1) showed that **1**

was glycosylated at the oxygen atom attached to C-1. A series of COSY and HMBC correlations (Figure 2) revealed that the sugar was a hexose. Finally, HMBC correlations from δ_H 3.76 (H-4') and 4.16 (H-5') to a carbonyl carbon at δ_C 173.0 (C-6') showed that the sugar had been oxidized to the carboxylic acid at C-6'.

The relative configuration of the sugar residue in **1** was determined by coupling constants and a NOESY experiment. Large coupling constants (J values ranged from 7.6 to 10.0 Hz; see Table 1) indicated that all of the protons must be axial, and therefore the sugar corresponds to β -glucuronic acid. This assignment was supported by NOESY correlations between δ_H 5.23 (H-1') and δ_H 3.63 (H-3'), between δ_H 5.23 (H-1') and δ_H 4.16 (H-5'), between δ_H 3.93 (H-2') and δ_H 3.76 (H-4'), and between δ_H 3.63 (H-3') and δ_H 4.16 (H-5') (Figure 3). The absolute configuration of the sugar moiety was not determined. The absolute configuration of C-12 was also not determined.




Figure 3. NOESY correlations in the sugar moiety of pseudonocardone A (1).

Pseudonocardone B (**2**) gave a peak in the HRESI(+) MS consistent with a molecular formula of $C_{26}H_{22}O_{10}$. The molecular formula of **2** differed from that of **1** by the loss of

Table 1. 1H and ^{13}C NMR Data for Pseudonocardones A (1), B (2), and C (3) Recorded in CD_3OD at 600 MHz

position	pseudonocardone A (1)		pseudonocardone B (2)		pseudonocardone C (3)	
	δ_C	δ_H (J in Hz)	δ_C	δ_H (J in Hz)	δ_C	δ_H (J in Hz)
1	156.9		154.7			
2	114.7	7.21, s	115.8	7.25, s	144.7	
3	140.5		141.8		134.7	
4	124.0	7.37, s	122.9	7.45, s	120.3	6.95, s
4a	139.4		135.4		131.9	
5	130.0	7.78, d (8.8)	134.4	8.06, d (8.2)	133.0	8.97, d (9.4)
6	124.5	8.10, d (8.2)	123.0	8.16, d (8.8)	122.8	8.17, d (8.8)
6a	132.5		135.0		137.1	
7	186.0		182.8		183.1	
7a	120.8		120.8		119.9	
8	161.1		160.3		160.5	
9	112.8	7.13, d (8.2)	118.3	7.47, d (8.8)	119.3	7.49, d (8.2)
10	136.0	7.64, t (7.9)	136.7	7.78, t (7.9)	136.5	7.75, t (7.9)
11	123.8	7.34, d (8.6)	119.3	7.62, d (7.6)	121.1	7.78, d (7.0)
11a	147.7		139.9		138.4	
12	66.5	6.93, s	189.5		190.8	
12a	139.6		138.8		133.2	
12b	121.6		119.5		121.0	
13	21.8	2.47, s	21.6	2.52, s	17.0	2.50, s
14	49.4	3.95, s	56.4	4.01, s	56.6	3.99, s
1'	103.8	5.23, d (7.6)	101.8	5.26, d (7.0)	106.6	4.76, d (7.6)
2'	75.0	3.93, t (8.8)	74.5	3.58, m	75.1	3.71, dd (9.1, 7.9)
3'	77.1	3.63, t (9.4)	77.1	3.59, m	77.2	3.50, t (9.1)
4'	73.1	3.76, t (9.4)	72.6	3.60, m	72.9	3.63, t (9.4)
5'	76.7	4.16, d (10.0)	76.1	3.98, d (9.4)	76.8	3.55, d (10.0)
6'	173.0		172.6		173.5	

two hydrogen atoms. The UV spectrum of **2** also differed significantly from that of **1**, with the low-energy λ_{\max} having shifted from 348 nm in **1** to 388 nm in **2**. The NMR data obtained for **2** were very similar to that of **1**, suggesting that the compounds were closely related. The NMR signals corresponding to the C-12 oxygenated methine present in **1** were absent from the NMR spectra of **2**. Instead, the resonance at δ_{H} 7.62 (H-11) showed an HMBC to a carbon at δ_{C} 189.5 (C-12), typical of a quinone carbon, revealing that **2** is the quinone analogue of **1**.

Pseudonocardone C (**3**) gave a peak in the HRESI(+) MS consistent with a molecular formula of $\text{C}_{26}\text{H}_{22}\text{O}_{11}$. The molecular formula of **3** differed from the molecular formula of **2** by the addition of an oxygen atom. The UV and NMR data obtained for **3** were very similar to that of **2**, suggesting that they are closely related. The aromatic singlet present in **2** at δ_{H} 7.25 (H-2) was absent in the NMR spectrum of **3**, and the other aromatic singlet at δ_{H} 7.45 (H-4) was shifted upfield to δ_{H} 6.95 (H-4) in **3**. The methyl resonance at δ_{H} 2.50 showed an HMBC correlation to a downfield carbon at δ_{C} 144.7 (C-2), suggesting that C-2 was substituted with an oxygen atom. An HMBC correlation from the anomeric proton at δ_{H} 4.76 (H-1') to C-2 showed that the sugar moiety was attached to C-2 instead of to C-1 as found in **1** and **2**. The lack of protons within three bonds from C-1 made the assignment of this position impossible to determine from the HMBC data. However, in order to satisfy the molecular formula of **3**, C-1 must be oxygenated as it is in **1**, **2**, and **5**.

Compounds **1–5** were tested for antibiotic activity against *Escherichia coli* K12, *Bacillus subtilis* 3610, *Candida albicans*, and *Saccharomyces cerevisiae*. Compounds **4** and **5** were active against *B. subtilis* 3610 with MIC values of 25 and 3.13 $\mu\text{g}/\text{mL}$, respectively. None of the compounds showed any activity against *E. coli*, *C. albicans*, or *S. cerevisiae* at concentrations as high as 50 $\mu\text{g}/\text{mL}$. Compounds **1–5** were also tested in a liver-stage malaria assay recently developed in one of our laboratories.¹⁴ Compounds **4** and **5** were active against liver-stage *Plasmodium berghei* with IC_{50} values of 18.5 and 3.0 μM , respectively. Finally, compounds **1–5** were tested for cytotoxicity against HepG2 cells. Compound **5** was active against HepG2 cells with an IC_{50} value of 36.1 μM . The glycoside analogues (**1–3**) were completely inactive against *B. subtilis*, *E. coli*, *C. albicans*, *S. cerevisiae*, and HepG2 cells at concentrations as high as 50 $\mu\text{g}/\text{mL}$ and showed only weak activity against liver-stage *P. berghei* with IC_{50} values of 38, 50, and >100 μM , respectively. The lack of activity for the glycosylated analogues provides insight into the structure–activity relationships of this family of compounds. A comparison of the activity of **2** with that of **5** shows that adding the glucuronic acid moiety at C-1 completely abolishes cytotoxic and antibiotic activity. Glycosylation of antibiotics has been proposed as one possible mechanism of self-resistance,^{15,16} and this might explain the lack of biological activity observed for **1–3**.

EXPERIMENTAL SECTION

General Experimental Procedures. An Agilent 1200 Series HPLC system equipped with a diode array detector and a Phenomenex C_{18} column (5 μm , 250 \times 21.2 mm) was used for preparative HPLC. For HPLC-MS analysis, an Agilent HPLC system equipped with a diode array detector and a 6130 Series quadrupole mass spectrometer was used with a Phenomenex C_{18} (5 μm , 100 \times 4.6 mm) column. The following gradient was used for HPLC-MS analysis:

Table 2. Cytotoxic Activities of **1–5** against HepG2 Cells and Antibiotic Activities of **1–5** against *P. berghei*, *E. coli*, *B. subtilis*, *C. albicans*, and *S. cerevisiae*^a

compound	HepG2	<i>P. berghei</i>	<i>E. coli</i>	<i>B. subtilis</i>	<i>C. albicans</i>	<i>S. cerevisiae</i>
	IC_{50} (μM)	IC_{50} (μM)	MIC ($\mu\text{g}/\text{mL}$)	MIC ($\mu\text{g}/\text{mL}$)	MIC ($\mu\text{g}/\text{mL}$)	MIC ($\mu\text{g}/\text{mL}$)
1	>100	38	>50	>50	>50	>50
2	>100	50	>50	>50	>50	>50
3	>100	>100	>50	>50	>50	>50
4	>100	18.5	>50	25	>50	>50
5	36.1	3.0	>50	3.13	>50	>50

^aData represent the average of two experiments each performed in triplicate. The MIC is defined as the lowest concentration that gave less than 5% of the maximum growth.

0–5 min, isocratic 10% CH_3CN + 0.1% formic acid; 5–25 min, linear gradient from 10% CH_3CN + 0.1% formic acid to 100% CH_3CN + 0.1% formic acid. NMR spectra were recorded in CD_3OD (for compounds **1–4**) or CD_2Cl_2 (for compound **5**) at 600 MHz and referenced to the internal solvent peak at δ_{H} 3.30 and δ_{C} 49.0 or δ_{H} 5.32 and δ_{C} 53.8, respectively. High-resolution mass spectrometry (HR-MS) was performed at the University of Illinois Urbana–Champaign Mass Spectrometry Facility.

Isolation of *Pseudonocardia* sp. EC080529-01. An ant colony of *A. dentigerum* was collected from Pipeline Road, Panama, on May 29, 2008, and placed in a sterile Petri dish with moist cotton. After allowing the nest to stabilize for a few days, the *Pseudonocardia* symbiont from this colony was isolated directly from the mesenteral lobe of a worker by scraping bacteria off the cuticle of the ant using a sterile scalpel and plating on chitin media following the methods of Caldera and Currie, and identified as *Pseudonocardia* sp. based on multilocus sequencing.¹⁰

Cultivation of *Pseudonocardia* sp. EC080529-01. Production cultures of *Pseudonocardia* sp. EC080529-01 were grown on solid ISP-2 medium (per liter: yeast extract, 4 g; malt extract, 10 g; glucose, 4 g) in 12 Petri plates (150 \times 20 mm, 1.2 L total) for 7 d at 30 °C. The solid agar was cut into small cubes and soaked in EtOAc (1.2 L) overnight. The EtOAc was filtered and dried *in vacuo* to give the crude EtOAc extract. The solid agar was re-extracted overnight with MeOH (1.2 L), and the MeOH was filtered and dried *in vacuo* to give the crude MeOH extract. The crude EtOAc extract was dissolved in 90% MeOH– H_2O (20 mL) and passed through a C_{18} column, eluting with additional 90% MeOH– H_2O , in order to remove nonpolar components. The eluent from this column was diluted with H_2O to give a final MeOH concentration of 60%. This solution was passed through another C_{18} column and washed with additional 60% MeOH– H_2O solution, followed by 100% MeOH. The 60% MeOH– H_2O fraction was purified by preparative HPLC using the following gradient: 0–5 min, isocratic 20% CH_3CN – H_2O ; 5–60 min, linear gradient from 20% CH_3CN – H_2O to 100% CH_3CN to give pure **4** (8.3 mg). The 100% MeOH fraction from this C_{18} column was purified by preparative HPLC using the following gradient: 0–10 min, isocratic 50% CH_3CN – H_2O ; 10–60 min, linear gradient from 50% CH_3CN – H_2O to 100% CH_3CN to give pure **5** (3.5 mg). The crude MeOH extract was dissolved in H_2O and passed through an HP-20 column. The HP-20 column was washed with water to remove polar components, and the compounds of interest were then eluted with 100% MeOH. The 100% MeOH fraction was dried *in vacuo*, redissolved in 60% MeOH– H_2O , and passed through a C_{18} column to remove nonpolar components. The eluent from this column was diluted with H_2O to give a final MeOH concentration of 30%. This solution was passed through another C_{18} column and washed with additional 30% MeOH– H_2O , followed by 100% MeOH. The 100% MeOH fraction from this C_{18} column was purified by reversed-phase HPLC using the following gradient: 0–10 min, isocratic 10% CH_3CN – H_2O + 0.1% formic acid; 10–60 min linear gradient from

10% CH₃CN–H₂O + 0.1% formic acid to 100% CH₃CN + 0.1% formic acid to give pure **1** (2.0 mg), **2** (0.9 mg), and **3** (1.8 mg).

Pseudonocardone A (1): colorless solid (2.0 mg); $[\alpha]_D^{20}$ –11 (c 0.02, MeOH); UV (MeOH) λ_{\max} (log ϵ) 310 nm (3.11), 279 (sh), 271 nm (3.59); ¹H NMR (600 MHz, CD₃OD) and ¹³C NMR (150 MHz, CD₃OD), see Table 1; (+)-HRESI *m/z* 497.1438 [M + H]⁺ (calcd for C₂₆H₂₅O₁₀, 497.1448).

Pseudonocardone B (2): yellow solid (0.9 mg); $[\alpha]_D^{20}$ –2 (c 0.02, MeOH); UV (MeOH) λ_{\max} (log ϵ) 377 nm (3.52), 305 nm (3.87); ¹H NMR (600 MHz, CD₃OD) and ¹³C NMR (150 MHz, CD₃OD), see Table 1; (+)-HRESI *m/z* 495.1295 [M + H]⁺ (calcd for C₂₆H₂₃O₁₀, 495.1291).

Pseudonocardone C (3): orange solid (1.8 mg); $[\alpha]_D^{20}$ –3 (c 0.09, MeOH); UV (MeOH) λ_{\max} (log ϵ) 403 nm (3.53), 314 nm (3.96); ¹H NMR (600 MHz, CD₃OD) and ¹³C NMR (150 MHz, CD₃OD) see Table 1; (+)-HRESI *m/z* 511.1229 (calcd for C₂₆H₂₃O₁₁, 511.1240).

Antibiotic Assays. The appropriate test organism was grown in a 5 mL culture overnight in either LB medium (for *E. coli* and *B. subtilis*) or YPD medium (for *C. albicans* and *S. cerevisiae*) at 30 °C. In each case, the overnight culture was diluted with additional sterile medium (LB or YPD) to an OD₆₀₀ of 0.01. Compounds **1–5** were dissolved in DMSO to give a concentration of 5 mg/mL and 2-fold serially diluted. These solutions (1 μ L) were added to the wells of a 96-well plate, followed by the diluted culture of the test organism (99 μ L) to give a final compound concentration ranging from 50 to 0.1 μ g/mL. The cultures were allowed to grow for 24 h at 30 °C before the OD₆₀₀ was measured using a plate reader. The MIC was defined as the lowest concentration that gave less than 5% of the maximum OD₆₀₀. Each antibiotic assay was performed in duplicate. Dynemicin A was used as a positive control and gave MIC values against *E. coli*, *B. subtilis*, *C. albicans*, and *S. cerevisiae* of 313, 0.16, 156, and 156 ng/mL, respectively.

Cytotoxic Assay. Compounds were tested for activity against HepG2 human hepatoma cells (ATCC) that were maintained in DMEM (Invitrogen), 10% FBS (Sigma), and 1% antibiotic–antimycotic (Invitrogen) in a standard tissue culture incubator (37 °C, 5% CO₂). For assays, compounds **1–5** (in DMSO) were added in triplicate to 15 000 cells in a 384-well plate. The final concentration of DMSO was 1%, and compounds varied from 0 to 50 μ g/mL. Cells were incubated with the compounds for 2 days at 37 °C, and then liver cell viability was assessed with CellTiter-Glo (Promega). The relative signal intensity of each sample was evaluated with an EnVision (PerkinElmer) system.

Liver-Stage *P. berghei* Assay. Liver-stage *P. berghei* assays were performed using a luciferase-expressing sporozoite strain of *P. berghei* ANKA. Parasites were obtained from dissection of *Plasmodium*-infected *Anopheles stephensi* mosquitoes (New York University Langone Medical Center Insectary). Malaria parasites (4000 sporozoites) were used to infect HepG2 cells (15 000 cells) in a 384-well plate in the presence of compounds **1–5** in triplicate. The final concentration of DMSO was 1%, and compounds varied from 0 to 50 μ g/mL. Cells were incubated with the compounds for 2 days at 37 °C, and then relative parasite load was determined after addition of Bright-Glo (Promega). Data analysis for HepG2 toxicity and liver-stage malaria activity was carried out using GraphPad Prism, and curves were fit with a standard inhibition dose–response curve to generate an IC₅₀ value. All statistical results are the mean IC₅₀ value averaged from two independent experiments. Atovaquone was used as a positive control and gave an IC₅₀ in blood stage assays of 0.3 nM.

■ ASSOCIATED CONTENT

📄 Supporting Information

HPLC-MS traces for compounds **1–3** and NMR spectra for compounds **1–5**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: (617) 432-2845. Fax: (617) 432-6424. E-mail: jon_clardy@hms.harvard.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by NIH RC4GM096347 (C.R.C. and J.C.), GM086258 (J.C.), and NSF CAREERDEB-747002 (C.R.C.), and a Ruth L. Kirschstein National Research Service Award F32GM093510 (E.R.D.).

■ REFERENCES

- (1) Cafaro, M. J.; Currie, C. R. *Can. J. Microbiol.* **2005**, *51*, 441–446.
- (2) Currie, C. R.; Scott, J. A.; Summerbell, R. C.; Malloch, D. *Nature* **1999**, *398*, 701–704.
- (3) Oh, D.-C.; Poulsen, M.; Currie, C. R.; Clardy, J. *Nat. Chem. Biol.* **2009**, *5*, 391–393.
- (4) Li, S.; Tian, X.; Niu, S.; Zhang, W.; Chen, Y.; Zhang, H.; Yang, X.; Zhang, W.; Li, W.; Zhang, S.; Ju, J.; Zhang, C. *Mar. Drugs* **2011**, *9*, 1428–1439.
- (5) Maskey, R. P.; Kock, I.; Helmke, E.; Laatsch, H. *Z. Naturforsch. B* **2003**, *58b*, 692–694.
- (6) Lee, M.-J.; Kong, D.; Han, K.; Sherman, D. H.; Bai, L.; Deng, Z.; Lin, S.; Kim, E.-S. *Appl. Microbiol. Biotechnol.* **2012**, *95*, 157–168.
- (7) Oh, D.-C.; Scott, J. J.; Currie, C. R.; Clardy, J. *Org. Lett.* **2009**, *11*, 633–636.
- (8) Oh, D.-C.; Poulsen, M.; Currie, C. R.; Clardy, J. *Org. Lett.* **2011**, *13*, 752–755.
- (9) Carr, G.; Poulsen, M.; Klassen, J. L.; Hou, Y.; Wyche, T. P.; Bugni, T. S.; Currie, C. R.; Clardy, J. *Org. Lett.* **2012**, *14*, 2822–2825.
- (10) Caldera, E. J.; Currie, C. R. *Am. Nat.* **2012**, in press.
- (11) Kharel, M. K.; Pahari, P.; Shepherd, M. D.; Tibrewal, N.; Nybo, S. E.; Shaaban, K. A.; Rohr, J. *Nat. Prod. Rep.* **2012**, *29*, 264–325.
- (12) Shighihara, Y.; Koizumi, Y.; Tamamura, T.; Homma, Y.; Isshiki, K.; Dobashi, K.; Naganawa, H.; Takeuchi, T. *J. Antibiot.* **1988**, *41*, 1260–1264.
- (13) Maeher, H.; Liu, C. M.; Liu, M.; Perrotta, A.; Smallheer, J. M.; Williams, T. H.; Blount, J. F. *J. Antibiot.* **1982**, *35*, 1627–1631.
- (14) Derbyshire, E. R.; Prudêncio, M.; Mota, M. M.; Clardy, J. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 8450–8455.
- (15) Zhao, L.; Sherman, D. H.; Liu, H.-W. *J. Am. Chem. Soc.* **1998**, *120*, 9374–9375.
- (16) Zhao, L.; Beyer, N. J.; Borisova, S. A.; Liu, H.-W. *Biochemistry* **2003**, *42*, 14794–14804.